Articles tagged "Immunosuppression"

2016 American Transplant Congress
Porcine Islets Engineered to Display SA-FasL Protein on Their Surface Induce Tolerance in Mice Following Transplantation into the Liver or Under the Kidney Capsule.
H. Zhao,¹ K. Woodward,¹ H. Shirwan,¹ M. Graham,² B. Hering,² E. Yolcu.¹
¹Institute for Cellular Therapeutics and Department of Microbiology and Immunology, University of Louisville, Louisville, KY; ²Schulze Diabetes Institute and Department of Surgery, University of Minnesota, Minneapolis, MN.
Introduction: We have recently demonstrated that allogeneic islets engineered to transiently display on their surface a novel form of FasL protein chimeric with streptavidin (SA-FasL)…
2016 American Transplant Congress
Designing a Novel Highly Selective Immunoproteasome Inhibitor That Promotes Longterm Heart Allograft Acceptance While Inducing Immune Cell Exhaustion, Treg Induction and Memory Cell Suppression.
E. Sula Karreci,¹ A. Mihali,¹ M. Uehara,¹ A. Kurdi,¹ L. Riella,¹ R. Abdi,¹ H. Fan,² P. Singh,² C. Nathan,² G. Lin,² J. Azzi.¹
¹Transplantation Research Center, Harvard Medical School, Boston, MA; ²Department of Microbiology and Immunology, Weill Cornell Medicine, New York City, NY.
The constitutive Proteasomes (c-20S) are ubiquitously expressed cellular proteases that degrade polyubiquitinated proteins and regulate cell functions. However, immunoproteasomes (IP or i-20S) are primarily expressed…
2016 American Transplant Congress
Evaluation of the Long-Term Outcomes with Everolimus After Calcineurin Inhibitor Withdrawal: 36M Results of the H2304 and PROTECT Extension Studies.
L. Fischer,^1,2 J. Fung,¹ H. Metselaar,¹ G. Kaiser,^1,2 P. Schemmer,² P. Neuhaus,² G. Dong,³ P. Lopez,⁴ P. Bernhardt,⁴ H. Schlitt.²
¹H2304 study group, Hamburg, Germany; ²PROTECT study group, Hamburg, Germany; ³Novartis Pharmaceuticals Corporation, East Hanover, NJ; ⁴Novartis Pharma AG, Basel, Switzerland.
Background: The H2304 and PROTECT studies demonstrated reduced nephrotoxicity with everolimus (EVR)-based calcineurin inhibitor (CNI; cyclosporine: CsA, tacrolimus: TAC)-free regimens at Month (M) 12. Here,…
2016 American Transplant Congress
Blockade of HLA Antibody-Triggered Classical Complement Activation by High-Affinity Humanized Monoclonal Anti-C1s Antibody TNT009 – Results of a First-in-Human Phase 1 Trial.
J. Mühbacher,¹ B. Jilma,² M. Wahrmann,³ L. Marinova,³ F. Eskandary,³ J. Gilbert,⁴ S. Panicker,⁴ G. Böhmig.³
¹Department of Surgery, Medical University of Vienna, Vienna, Austria; ²Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria; ³Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria; ⁴True North Therapeutics, Inc., South San Francisco, CA.
Study purpose: Classical complement may play a key role in ABMR. A promising therapeutic approach could be complement inhibition at the level of key component…
2016 American Transplant Congress
Soluble Fibrinogen-Like Protein 2 Regulates Differentiation and Enhances Immunosuppressive Function of Myeloid-Derived Suppressor Cells in Allograft Immunity.
C. Yang,^1,4 L. Wang,³ R. Rong,^2,4 T. Zhu,^2,4 M. Xu.^2,4
¹Plastic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China; ²Urology, Zhongshan Hospital, Fudan University, Shanghai, China; ³Biomedical Research Center, Zhongshan Hospital, Fudan University, Shanghai, China; ⁴Shanghai Key Laboratory of Organ Transplantation, Shanghai, China.
Soluble fibrinogen-like protein 2 (sFGL2) is a novel immunoregulatory molecule, secreted mainly by regulatory T cells. CD11b+ Gr1+ myeloid-derived suppressor cells (MDSCs) are an important…
2016 American Transplant Congress
Monocytic TNF-α Response to EBV Peptides as a Mean to Identify Over-Immunosuppressed Kidney Transplant Recipients.
P. Vallin,¹ O. Désy,¹ S. Béland,¹ E. Wagner,² S. De Serres.¹
¹Renal Division, Quebec University Health Center, Laval University, Quebec, QC, Canada; ²Immunology and Histocompatibility Laboratory, Quebec University Health Center, Laval University, Quebec, QC, Canada.
Background. The reduction in acute rejection rates seen with the current triple immunosuppressive maintenance regimen has come at the expense of an increased risk of…
2016 American Transplant Congress
A Randomized-Controlled Trial Comparing the Efficacy of CYP3A5 Genotype-Based with Bodyweight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation.
N. Shuker,^1,2 R. Bouamar,² R. van Schaik,³ M. Clahsen -van Groningen,⁴ J. Damman,⁵ C. Baan,¹ J. van de Wetering,¹ A. Rowshani,¹ W. Weimar,¹ T. van Gelder,^1,2 D. Hesselink.¹
¹Internal Medicine, Erasmus Medical Centre, Rotterdam, Netherlands; ²Hospital Pharmacy, Erasmus Medical Centre, Rotterdam, Netherlands; ³Clinical Chemistry, Erasmus Medical Centre, Rotterdam, Netherlands; ⁴Pathology, Erasmus Medical Centre, Rotterdam, Netherlands; ⁵Pathology, Academic Medical Centre, Amsterdam, Amsterdam, Netherlands.
Patients expressing the cytochrome P450 (CYP) 3A5 gene require a higher tacrolimus dose to achieve therapeutic exposure compared with non-expressers. This randomized-controlled study investigated if…
2016 American Transplant Congress
Comparison of Actual versus Goal Tacrolimus Levels Post Cardiothoracic Transplant.
E. Milas, I. Feurer, C. Truscott, J. Gray, N. Wilson, S. Bala, T. Dreher, M. Wigger, M. Steele, A. Shah, E. Lambright, D. Hanto.
Vanderbilt Transplant Center, Nashville, TN.
BackgroundAlthough target tacrolimus (TAC) trough levels necessary to prevent rejection are established post heart/lung transplant (tx), there is little published literature on the proportion of…
2016 American Transplant Congress
Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus: A Cost-Effectiveness Analyses.
H. Tedesco-Silva, C. Felipe, A. Brigido, M. Cristelli, M. Paula, A. Bessa, P. Ruppel, J. Medina-Pestana.
Nephrology Division, Hospital do Rim - UNIFESP, Sao Paulo, Brazil.
A cost-effectiveness analysis was performed using data from a prospective single center trial where de novo kidney transplant recipients received a single 3 mg/kg dose…
2016 American Transplant Congress
Clinical and Immunologic Assessments of Immune Responses in a Liver Transplant Patient with CD40L Deficiency and Hyper IgM Syndrome.
M. Tseng,¹ S. Ge,¹ R. Roberts,² C. Kuo,² J. Choi,¹ N. Nissen,¹ M. Chu,¹ I. Kim,¹ B. Shin,¹ M. Toyoda,¹ S. Jordan.¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Pediatrics & Immunology, UCLA, Los Angeles, CA.
Introduction: Monoclonal antibodies that disrupt CD40/CD40 ligand (CD40L) interactions are likely to have utility in human transplantation. However, the extent of the immunosuppressive effects of…